Growing demand for cardiovascular clinical trials used for Stroke to drive market demand.

Published: Nov 2023

The global cardiovascular clinical trials market is anticipated to grow at a CAGR of 9.4% during the forecast period (2023-2030). The key factors for the promising growth of global cardiovascular clinical trials market are increasing number of patients undergoing stroke, technological advancements, enhancement in health facilities, rising healthcare investments, and increasing change in lifestyle related diseases such as obesity which is the major cause of increasing stroke incidences. According to the World Stroke Organization 2022, there are 12.2 million new strokes per year one every 3 seconds around the globe. There are 101 million people around the globe are living with stroke aftermath. this number has almost doubled over the last 30 years. Further, 1 in 4 people will have a stroke in their lifetime this number has increased 50.0% over the last 17 years. Up to 80.0% of strokes and heart attacks happen in people with 63% low or moderate CVD absolute risk. In 2019, 63.0% of stroke happened in people younger than 70 years old. Moreover, growing cases of stroke in various nations across the globe have led to increased need for cardiovascular clinical trials and it has generated maximum revenue in recent times. Some of the key participating global cardiovascular clinical trials market are IQVIA Inc, ICON plc, Medpace, Inc., NoyMed CRO, Eli Lilly and Co. 

Browse the full report description of “Cardiovascular Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, and Phase IV), by Study Design (Observational, Interventional, and Expanded Access), by Indication (Coronary Artery Disease, Acute Coronary Syndrome, Pulmonary Arterial Hypertension, Ischemic Heart Disease, Stroke, Heart Failure, and Others), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/cardiovascular-clinical-trials-market

The increasing affiliation between the institutions aims to enhance the understanding, prevention, and treatment of cardiovascular disease, and develop new strategies to combat this global health challenge. For instance, in September 2023, Icahn School of Medicine at Mount Sinai signed a memorandum of understanding with the Brazilian Clinical Research Institute (BCRI) to focus on advancing cardiovascular disease research, innovation, and medical education. Under this partnership, Mount Sinai and BCRI launched international research programs and clinical trials on heart disease, including a focus on preventing and treating heart attacks and strokes. Furthermore, in August 2023, Early phase clinical research organization Dr. Vince Clinical Research (DVCR) formed a strategic alliance with Clario for delivering cardiac assessments in clinical trials. The strategic partnership extended access to the Early Precision QT (EPQT) methodology of Clario. Through this partnership, DVCR used the technology with a Wi-Fi-enabled 12-lead telemetry system. This system archives data on-site and directly uploads it to the Cloud-based portal of Clario.

Market Coverage

The market number available for – 2022-2030

Base year- 2022

Forecast period- 2023-2030

Segment Covered- 

o By Phase

o By Study Design

o By Indication

Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape- includes IQVIA Inc, ICON plc, Medpace, Inc., NoyMed CRO, Eli Lilly and Co., and others.

Key questions addressed by the report

What is the market growth rate?

Which segment and region dominate the market in the base year?

Which segment and region will project the fastest growth in the market?

Who is the leader in the market?

How are players addressing challenges to sustain growth?

Where is the investment opportunity?

Global Cardiovascular Clinical Trials Market Report Segment

By Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Study Design

  • Observational
  • Interventional
  • Expanded Access

By Indication

  • Coronary Artery Disease
  • Acute Coronary Syndrome
  • Pulmonary Arterial Hypertension
  • Ischemic Heart Disease
  • Stroke
  • Heart Failure
  • Others (Cardiac Arrhythmias)

Global Cardiovascular Clinical Trials Market Report Segment by Region

North America

United States

Canada

Europe

UK

Germany

Italy

Spain

France

Rest of Europe 

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific 

Rest of the World

Latin America 

Middle East & Africa


To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/cardiovascular-clinical-trials-market